指南与共识儿科与产科急症

产科医疗共识第6号摘要:围存活期分娩

Obstetric Care Consensus No. 6 Summary: Periviable Birth.
指南 / 共识 · Obstet Gynecol · 2017-01-01
一句话结论围存活期分娩定义为妊娠20 0/7周至25 6/7周分娩,需结合多种因素进行个体化决策与家庭咨询。

该共识将围存活期分娩定义为妊娠20 0/7周至25 6/7周的分娩,此阶段分娩占新生儿死亡的大多数及婴儿死亡的40%以上。除胎龄外,胎儿性别、体重、多胎、分娩地点、产前皮质类固醇和硫酸镁使用、产后重症监护的启动或撤除等因素均与围存活期分娩的短期和长期结局相关。产前和产时管理选项包括短期宫缩抑制治疗、抗生素及分娩方式选择。计划干预的围存活期分娩应尽可能在具备母胎和新生儿重症监护专长的中心进行。文件提供基于证据的建议和家庭咨询框架,以纳入患者偏好。

要点

  • 围存活期分娩定义为妊娠20 0/7周至25 6/7周的分娩,此阶段分娩导致大多数新生儿死亡和超过40%的婴儿死亡。
  • 除胎龄外,不可改变因素(如胎儿性别、体重、多胎)、可改变因素(如分娩地点、产前皮质类固醇和硫酸镁使用)及产后管理均与结局相关。
  • 产前和产时管理选项包括短期宫缩抑制治疗以争取产前皮质类固醇给药时间、抗生素以延长胎膜早破后潜伏期或产时B族链球菌预防,以及因胎儿状况或胎位异常而行的剖宫产。
  • 计划母体或新生儿干预的围存活期分娩应尽可能在具备母胎和新生儿重症监护专长的中心进行。
  • 文件旨在提供基于个体情况和患者价值的决策支持,包括拒绝和接受干预及治疗。

适用人群与场景

  • 妊娠20 0/7周至25 6/7周面临分娩的孕妇及其家庭
  • 计划进行母体或新生儿干预的围存活期分娩

诊断标准与关键阈值

  • 围存活期分娩定义为妊娠20 0/7周至25 6/7周的分娩

处置流程与药物剂量

  • 短期宫缩抑制治疗用于早产临产,以争取产前皮质类固醇给药时间
  • 抗生素用于胎膜早破后延长潜伏期或产时B族链球菌预防
  • 因胎儿状况或胎位异常考虑剖宫产分娩
  • 计划干预的围存活期分娩应尽可能在具备母胎和新生儿重症监护专长的中心进行

研究设计与关键结果

  • 约0.5%的分娩发生在妊娠第三孕期之前,这些极早产导致大多数新生儿死亡和超过40%的婴儿死亡

证据类型、等级与局限

  • 证据类型:产科医疗共识(指南)
  • 局限:原文未报告局限性

对床旁实践的改变

  • 临床决策需结合胎龄外的多种因素(如胎儿性别、体重、多胎、分娩地点、产前皮质类固醇和硫酸镁使用、产后监护选择)进行个体化评估
  • 家庭咨询应纳入患者偏好,支持基于个体情况和价值的决策,包括拒绝和接受干预

指南或共识出处

  • 产科医疗共识第6号摘要:围存活期分娩(Obstetric Care Consensus No. 6 Summary: Periviable Birth),Obstet Gynecol

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Approximately 0.5% of all births occur before the third trimester of pregnancy, and these very early deliveries result in the majority of neonatal deaths and more than 40% of infant deaths. A recent executive summary of proceedings from a joint workshop defined periviable birth as delivery occurring from 20 0/7 weeks to 25 6/7 weeks of gestation. When delivery is anticipated near the limit of viability, families and health care teams are faced with complex and ethically challenging decisions. Multiple factors have been found to be associated with short-term and long-term outcomes of periviable births in addition to gestational age at birth. These include, but are not limited to, nonmodifiable factors (eg, fetal sex, weight, plurality), potentially modifiable antepartum and intrapartum factors (eg, location of delivery, intent to intervene by cesarean delivery or induction for delivery, administration of antenatal corticosteroids and magnesium sulfate), and postnatal management (eg, starting or withholding and continuing or withdrawing intensive care after birth). Antepartum and intrapartum management options vary depending upon the specific circumstances but may include short-term tocolytic therapy for preterm labor to allow time for administration of antenatal steroids, antibiotics to prolong latency after preterm premature rupture of membranes or for intrapartum group B streptococci prophylaxis, and delivery, including cesarean delivery, for concern regarding fetal well-being or fetal malpresentation. Whenever possible, periviable births for which maternal or neonatal intervention is planned should occur in centers that offer expertise in maternal and neonatal care and the needed infrastructure, including intensive care units, to support such services. This document describes newborn outcomes after periviable birth, provides current evidence and recommendations regarding interventions in this setting, and provides an outline for family counseling with the goal of incorporating informed patient preferences. Its intent is to provide support and guidance regarding decisions, including declining and accepting interventions and therapies, based on individual circumstances and patient values.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

参考来源

  1. Obstetric Care Consensus No. 6 Summary: Periviable Birth. Obstet Gynecol. 2017. PMID: 28937567. doi:10.1097/AOG.0000000000002347

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。